PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
3.75%
Positive revenue growth while 3088.T is negative. John Neff might see a notable competitive edge here.
10.29%
Gross profit growth above 1.5x 3088.T's 0.85%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
11.03%
EBIT growth 50-75% of 3088.T's 15.11%. Martin Whitman would suspect suboptimal resource allocation.
42.26%
Operating income growth above 1.5x 3088.T's 6.18%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
26.24%
Net income growth 1.25-1.5x 3088.T's 17.51%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
26.24%
EPS growth 1.25-1.5x 3088.T's 17.53%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
26.24%
Diluted EPS growth 1.25-1.5x 3088.T's 17.53%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
0.00%
Share change of 0.00% while 3088.T is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
8.65%
10Y revenue/share CAGR under 50% of 3088.T's 32.33%. Michael Burry would suspect a lasting competitive disadvantage.
-2.00%
Negative 5Y CAGR while 3088.T stands at 29.24%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-30.84%
Negative 3Y CAGR while 3088.T stands at 13.76%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-100.00%
Negative 10Y OCF/share CAGR while 3088.T stands at 100.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-100.00%
Negative 5Y OCF/share CAGR while 3088.T is at 100.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
No Data
No Data available this quarter, please select a different quarter.
51.37%
Net income/share CAGR at 50-75% of 3088.T's 97.79%. Martin Whitman might question if the firm’s product or cost base lags behind.
22.70%
Below 50% of 3088.T's 1533.74%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-13.67%
Negative 3Y CAGR while 3088.T is 35.91%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
62.70%
10Y equity/share CAGR in line with 3088.T's 65.44%. Walter Schloss might see both benefiting from stable profitability and moderate payout ratios over the decade.
33.26%
5Y equity/share CAGR at 50-75% of 3088.T's 55.29%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
-10.59%
Negative 3Y equity/share growth while 3088.T is at 38.67%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
-45.83%
Cut dividends over 10 years while 3088.T stands at 15943.73%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
41.30%
Below 50% of 3088.T's 17280.71%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
-26.14%
Negative near-term dividend growth while 3088.T invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
25094.44%
AR growth of 25094.44% while 3088.T is zero. Bruce Berkowitz wonders if the firm’s additional AR is warranted by strong revenue or potential risk.
-1.93%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
3.97%
Positive asset growth while 3088.T is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
5.74%
1.25-1.5x 3088.T's 4.15%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
54.19%
We have some new debt while 3088.T reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-41.59%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.